| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/300 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/10000 | Human,Mouse,Rat |
| Aliases | MEK2, MKK2, MAPKK2, PRKMK2 |
| WB Predicted band size | 44 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human MAP2K2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇与MAP2K2抗体相关的文献示例(内容基于公开研究整理)：
1. **文献名称**：*"Validation of a specific MEK2 antibody for immunohistochemical analysis of RAS/ERK pathway activation"*
**作者**：Li et al. (2018)
**摘要**：本研究验证了一种高特异性MAP2K2(MEK2)抗体在石蜡包埋组织中的免疫组化应用，证实其可检测MEK2蛋白表达水平，并与结直肠癌患者RAS/ERK信号通路激活程度相关。
2. **文献名称**：*"MEK2 knockdown reveals distinct roles in cardiomyocyte survival via antibody-based functional screening"*
**作者**：Sato et al. (2015)
**摘要**：通过siRNA敲低结合MAP2K2抗体的Western blot验证，发现MEK2在心肌细胞凋亡调控中具有独立于MEK1的作用，抗体特异性经HEK293细胞过表达模型确认。
3. **文献名称**：*"Antibody profiling of MAPK signaling components in melanoma drug resistance"*
**作者**：Garcia et al. (2020)
**摘要**：采用多种MAP2K2商业化抗体(包括CST #D1A9F)进行磷酸化位点分析，揭示MEK2的活性状态与BRAF抑制剂耐药性相关，抗体特异性通过肽段竞争实验验证。
---
**注**：以上文献信息为示例性描述，实际引用需以真实论文数据为准。建议通过PubMed或Google Scholar搜索关键词“MAP2K2 antibody validation”或“MEK2 antibody application”获取最新文献。部分权威抗体生产商(如Cell Signaling Technology)官网也会提供相关抗体的引用文献。
The MAP2K2 antibody is a crucial tool in studying the mitogen-activated protein kinase kinase 2 (MAP2K2), also known as MEK2. a dual-specificity serine/threonine kinase within the MAPK/ERK signaling pathway. MAP2K2 plays a pivotal role in transducing extracellular signals, such as growth factors and cytokines, into intracellular responses by phosphorylating and activating ERK1/2 kinases. This pathway regulates cell proliferation, differentiation, survival, and apoptosis, making it central to development, oncogenesis, and therapeutic resistance. Dysregulation of MAP2K2 is linked to cancers (e.g., melanoma, colorectal cancer), developmental disorders, and autoimmune diseases.
MAP2K2 antibodies are widely used in Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry to detect protein expression, phosphorylation status, and localization in tissues or cell lines. They aid in studying pathway activation, drug response (e.g., MEK inhibitors in cancer), and genetic mutations (e.g., BRAF-driven resistance). Researchers also utilize these antibodies to validate CRISPR/Cas9 knockouts or siRNA-mediated knockdowns.
Most MAP2K2 antibodies target specific epitopes, such as the N-terminal catalytic domain or phosphorylated residues (e.g., Ser222/226), enabling precise mechanistic insights. Polyclonal and monoclonal variants are available, with validation often including knockout cell line controls. Due to pathway crosstalk and isoform homology (e.g., MAP2K1/MEK1), antibody specificity is critical for accurate data interpretation. Commercial antibodies are typically validated across applications, but batch variability remains a consideration. Overall, MAP2K2 antibodies are indispensable for dissecting ERK signaling dynamics in health and disease.
×
